Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Whole Genome Sequencing (WGS) and transcriptome analysis | Experimental | to investigate by WGS analysis the genome of selected patients with a detailed clinical characterization. WGS will be also performed on the DNA of the parent from which originated the CNV to look for any potential genomic signatures predisposing to the rearrangement detected in his/her son/daughter. to investigate the expression profiles of structural variants by transcriptome analysis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WGS and transcriptome analysis | Diagnostic Test | In light of the inconsistencies between the CNV and the phenotypic outcome, we expect that WGS analysis will reveal that part of these CNVs have a more complex structure than the one disentangled by CMA and FISH. We hypothesize that CNV should reflect a perturbed genome folding configuration at several hierarchical levels of chromatin organization, such as disruption of TADs boundaries. To investigate this aspect, we plan to examine expression profiles of immortalized lymphoblastoid B-cell lines (LBLs) derived from normal controls and patients. We expect to find a subset of down- or up-regulated genes located inside the rearranged region which in turn may alter the expression of other genes, possibly leading to perturbation of disease-related pathways |
| Measure | Description | Time Frame |
|---|---|---|
| Number of likely pathogenic structural variants | Number of likely pathogenic structural variants found by whole genome sequencing and transcriptome analysis. | once at recruitment |
| Number of patients for whom a genotype-phenotype correlation is found | Number of patients for whom a genotype-phenotype correlation is found based on results of whole genome sequencing and transcriptome analysis. | once at recruitment |
Not provided
Not provided
Inclusion Criteria:
Patients with neurodevelopmental disorders carrying a genomic rearrangement identified through chromosomal microarray analysis (CMA)
Exclusion Criteria:
NA
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Scientific Institute IRCCS Eugenio Medea | Bosisio Parini | LC | 23842 | Italy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D065886 | Neurodevelopmental Disorders |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D059467 | Transcriptome |
| ID | Term |
|---|---|
| D014158 | Transcription, Genetic |
| D001669 | Biochemical Phenomena |
| D055598 | Chemical Phenomena |
| D015870 | Gene Expression |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| D055614 |
| Genetic Phenomena |
| D040342 | Genetic Structures |